To investigate in this phase 2a study ( ZENITH ) the safety , tolerability , and antiviral activity of VX-222 , a selective , non-nucleoside inhibitor of hepatitis C virus ( HCV ) NS5B polymerase , combined with various telaprevir-based regimens for treatment of genotype 1 HCV .